These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 35241123)

  • 41. Disease-Modifying Therapies for Sickle Cell Disease-An Overview.
    Peddinti R
    Pediatr Ann; 2024 Feb; 53(2):e52-e55. PubMed ID: 38302121
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Allogeneic stem cell transplantation for sickle cell disease.
    Robinson TM; Fuchs EJ
    Curr Opin Hematol; 2016 Nov; 23(6):524-529. PubMed ID: 27496639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Voxelotor for the treatment of sickle cell disease.
    Vissa M; Vichinsky E
    Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
    [No Abstract]   [Full Text] [Related]  

  • 44. Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium.
    Masese RV; Bulgin D; Knisely MR; Preiss L; Stevenson E; Hankins JS; Treadwell MJ; King AA; Gordeuk VR; Kanter J; Gibson R; Glassberg JA; Tanabe P; Shah N;
    PLoS One; 2021; 16(10):e0258638. PubMed ID: 34714833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastrointestinal and hepatic complications of sickle cell disease.
    Ebert EC; Nagar M; Hagspiel KD
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):483-9; quiz e70. PubMed ID: 20215064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Use of Disease-Modifying Treatments in Patients With Sickle Cell Disease.
    Newman TV; Yang J; Suh K; Jonassaint CR; Kane-Gill SL; Novelli EM
    JAMA Netw Open; 2023 Nov; 6(11):e2344546. PubMed ID: 37991760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sickle cell disease in the new era: advances in drug treatment.
    Lee MT; Ogu UO
    Transfus Apher Sci; 2022 Oct; 61(5):103555. PubMed ID: 36096995
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sickle Cell Disease: A Brief Update.
    Azar S; Wong TE
    Med Clin North Am; 2017 Mar; 101(2):375-393. PubMed ID: 28189177
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Haploidentical Allogeneic Stem Cell Transplantation in Sickle Cell Disease: A Systematic Review and Meta-Analysis.
    Aydin M; Dovern E; Leeflang MMG; de la Fuente J; Kassim AA; Biemond BJ; Nur E
    Transplant Cell Ther; 2021 Dec; 27(12):1004.e1-1004.e8. PubMed ID: 34537420
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sickle cell disease: current treatment and emerging therapies.
    Neumayr LD; Hoppe CC; Brown C
    Am J Manag Care; 2019 Nov; 25(18 Suppl):S335-S343. PubMed ID: 31809007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current and emerging drug treatment strategies to tackle sickle cell anemia.
    Persaud Y; Leonard A; Rai P
    Expert Opin Emerg Drugs; 2024 Dec; 29(4):327-346. PubMed ID: 38988318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
    Soni S; Gross TG; Rangarajan H; Baker KS; Sturm M; Rhodes M
    Pediatr Blood Cancer; 2014 Sep; 61(9):1685-9. PubMed ID: 24740582
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials.
    Ali MA; Ahmad A; Chaudry H; Aiman W; Aamir S; Anwar MY; Khan A
    Exp Hematol; 2020 Dec; 92():11-18.e1. PubMed ID: 32841705
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular and environmental contributors to neurological complications in sickle cell disease.
    Karkoska KA; Gollamudi J; Hyacinth HI
    Exp Biol Med (Maywood); 2023 Aug; 248(15):1319-1332. PubMed ID: 37688519
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
    Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective.
    Dela-Pena JC; King MA; Brown J; Nachar VR
    J Oncol Pharm Pract; 2022 Apr; 28(3):646-663. PubMed ID: 35060419
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Haploidentical stem cell transplantation for patients with sickle cell disease: current status.
    Pawlowska AB; Sun V; Rosenthal J
    Transfus Apher Sci; 2022 Oct; 61(5):103534. PubMed ID: 36089470
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment.
    Dobie G
    Clin Lab; 2023 Jul; 69(7):. PubMed ID: 37436376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.